CRVO
CervoMed Inc.NASDAQHealthcare$4.14+3.50%ClosedMarket Cap: $38.3M
As of 2026-04-06
Valuation
View DetailsP/E (TTM)
—
PEG
—
P/B
2.02
P/S
114.24
EV/EBITDA
-1.02
DCF Value
$20.10
FCF Yield
-63.6%
Div Yield
0.0%
Margins & Returns
Gross Margin
100.0%
Operating Margin
-8771.7%
Net Margin
-8359.9%
ROE
-96.0%
ROA
-115.2%
ROIC
-151.0%
Financials
View All| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q4 2025 | $0.00 | $-8.1M | $-0.87 |
| FY 2025 | $4.0M | $-27.0M | $-2.98 |
| Q3 2025 | $322.6K | $-7.7M | $-0.84 |
| Q2 2025 | $0.00 | $-6.3M | $-0.70 |
Analyst Ratings
View AllD. Boral CapitalBuy
2026-03-19Roth CapitalBuy
2026-03-18Chardan CapitalBuy
2026-03-18HC Wainwright & Co.Buy
2025-12-18D. Boral CapitalBuy
2025-12-05Trading Activity
Insider Trades
View AllWinton Matthewofficer: Chief Commercial and Business
SellFri Feb 13
Gregoire Sylviedirector, 10 percent owner:
SellFri Feb 13
ELDER WILLIAM ROBERTofficer: CFO, GC & Secretary
SellFri Feb 13
De Rosch Markofficer: EVP, RA and GA and PgM
SellFri Feb 13
Blackburn Kellyofficer: EVP, Clinical Development
SellFri Feb 13
Company Info
Sector
Healthcare
Industry
—
Country
US
Exchange
NASDAQ
Beta
-5.04
CervoMed Inc., a clinical-stage biotechnology company, engages in the development and commercialization of drug treatments for neurodegenerative diseases. It develops neflamapimod, an orally administered small molecule brain penetrant for the treatment of dementia with Lewy bodies (DLB), Alzheimer's diseases, and brain stroke recovery. The company is based in Boston, Massachusetts.